| Literature DB >> 21067923 |
Charles Z Ding1, Yong-Kang Zhang, Xianfeng Li, Yang Liu, Suoming Zhang, Yasheen Zhou, Jacob J Plattner, Stephen J Baker, Liang Liu, Maosheng Duan, Richard L Jarvest, Jingjing Ji, Wieslaw M Kazmierski, Matthew D Tallant, Lois L Wright, Gary K Smith, Renae M Crosby, Amy A Wang, Zhi-Jie Ni, Wuxin Zou, Jon Wright.
Abstract
We disclose here a series of P4-benzoxaborole-substituted macrocyclic HCV protease inhibitors. These inhibitors are potent against HCV NS3 protease, their anti-HCV replicon potencies are largely impacted by substitutions on benzoxaborole ring system and P2∗ groups. P2∗ 2-thiazole-isoquinoline provides best replicon potency. The in vitro SAR studies and in vivo PK evaluations of selected compounds are described herein.Entities:
Mesh：
Substances：
Year: 2010 PMID： 21067923 DOI： 10.1016/j.bmcl.2010.10.071
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823